Untangling the Multidisciplinary Care Web: Streamlining Care Through an Immune-Related Adverse Events (IRAE) Tumor Board

被引:12
作者
Kennedy, Laura C. [1 ,2 ,3 ]
Wong, Kit Man [1 ,2 ,3 ]
Kamat, Nikhil V. [1 ,2 ,3 ]
Khaki, Ali Raza [1 ,2 ,3 ]
Bhatia, Shailender [1 ,2 ,3 ]
Thompson, John A. [1 ,2 ,3 ]
Grivas, Petros [1 ,2 ,3 ]
机构
[1] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA
[2] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle Canc Care Alliance, 1144 Eastlake Ave E,LG-465, Seattle, WA 98109 USA
[3] Seattle Canc Care Alliance, Seattle, WA 98109 USA
关键词
CANCER-IMMUNOTHERAPY; MANAGEMENT; DISEASE;
D O I
10.1007/s11523-020-00739-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immune-related adverse events (IRAEs) are becoming increasingly common as the use of immune checkpoint inhibitors expands into more tumor types and treatment settings. Although the majority of IRAEs are mild and can be managed in the outpatient setting by the medical oncologist, severe IRAEs can be life threatening and often require complex care coordination among multiple providers. These providers include a variety of non-oncology specialists who have interest and expertise in managing IRAEs. Multiple systems-based solutions have been proposed in the literature, but these need to be tailored to the needs and resources of each practice setting. In this article, we highlight the challenges of IRAE care by presenting an illustrative case from our institution. We then describe the format and structure of the IRAE Tumor Board established at the University of Washington/Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center. Finally, we discuss how this tumor board attempts to address clinical issues related to complex IRAE presentations and provide IRAE education.
引用
收藏
页码:541 / 548
页数:8
相关论文
共 21 条
[1]   Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes [J].
Balaji, Aanika ;
Zhang, Jiajia ;
Wills, Beatriz ;
Marrone, Kristen A. ;
Elmariah, Hany ;
Yarchoan, Mark ;
Zimmerman, Jacquelyn W. ;
Hajjir, Khalid ;
Venkatraman, Deepti ;
Armstrong, Deborah K. ;
Laheru, Daniel A. ;
Mehra, Ranee ;
Ho, Won Jin ;
Reuss, Joshua E. ;
Heng, Joseph ;
Vellanki, Paz ;
Donehower, Ross C. ;
Holdhoff, Matthias ;
Naidoo, Jarushka .
JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (09) :494-+
[2]   Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].
Brahmer, Julie R. ;
Lacchetti, Christina ;
Schneider, Bryan J. ;
Atkins, Michael B. ;
Brassil, Kelly J. ;
Caterino, Jeffrey M. ;
Chau, Ian ;
Ernstoff, Marc S. ;
Gardner, Jennifer M. ;
Ginex, Pamela ;
Hallmeyer, Sigrun ;
Chakrabarty, Jennifer Holter ;
Leighl, Natasha B. ;
Mammen, Jennifer S. ;
McDermott, David F. ;
Naing, Aung ;
Nastoupil, Loretta J. ;
Phillips, Tanyanika ;
Porter, Laura D. ;
Puzanov, Igor ;
Reichner, Cristina A. ;
Santomasso, Bianca D. ;
Seigel, Carole ;
Spira, Alexander ;
Suarez-Almazor, Maria E. ;
Wang, Yinghong ;
Weber, Jeffrey S. ;
Wolchok, Jedd D. ;
Thompson, John A. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+
[3]  
Cole Suzanne, 2019, Am Soc Clin Oncol Educ Book, V39, P96, DOI 10.1200/EDBK_100018
[4]   Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy [J].
Haanen, J. ;
Ernstoff, M. S. ;
Wang, Y. ;
Menzies, A. M. ;
Puzanov, I. ;
Grivas, P. ;
Larkin, J. ;
Peters, S. ;
Thompson, J. A. ;
Obeid, M. .
ANNALS OF ONCOLOGY, 2020, 31 (06) :724-744
[5]   Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Haanen, J. B. A. G. ;
Carbonnel, F. ;
Robert, C. ;
Kerr, K. M. ;
Peters, S. ;
Larkin, J. ;
Jordan, K. .
ANNALS OF ONCOLOGY, 2017, 28 :119-142
[6]   Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs [J].
Haslam, Alyson ;
Prasad, Vinay .
JAMA NETWORK OPEN, 2019, 2 (05)
[7]   Preexisting Autoimmune Disease: Implications for Immune Checkpoint Inhibitor Therapy in Solid Tumors [J].
Kennedy, Laura C. ;
Bhatia, Shailender ;
Thompson, John A. ;
Grivas, Petros .
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2019, 17 (06) :750-757
[8]   Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma [J].
Larkin, J. ;
Chiarion-Sileni, V. ;
Gonzalez, R. ;
Grob, J-J ;
Rutkowski, P. ;
Lao, C. D. ;
Cowey, C. L. ;
Schadendorf, D. ;
Wagstaff, J. ;
Dummer, R. ;
Ferrucci, P. F. ;
Smylie, M. ;
Hogg, D. ;
Hill, A. ;
Marquez-Rodas, I. ;
Haanen, J. ;
Guidoboni, M. ;
Maio, M. ;
Schoffski, P. ;
Carlino, M. S. ;
Lebbe, C. ;
McArthur, G. ;
Ascierto, P. A. ;
Daniels, G. A. ;
Long, G. V. ;
Bastholt, L. ;
Rizzo, J. I. ;
Balogh, A. ;
Moshyk, A. ;
Hodi, F. S. ;
Wolchok, J. D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16) :1535-1546
[9]  
Larkin J, 2015, NEW ENGL J MED, V373, P1270, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
[10]   Patient Education Issues and Strategies Associated With Immunotherapy [J].
Lasa-Blandon, Marlon ;
Stasi, Kristen ;
Hehir, Ashley ;
Fischer-Cartlidge, Erica .
SEMINARS IN ONCOLOGY NURSING, 2019, 35 (05)